Therapeutic potential of yeast killer toxin-like antibodies and mimotopes

FEMS Yeast Research

Volumn 5, Issue 1, 2004, Pages 11-18

  Magliani, Walter ^a   Conti, Stefania ^a   Salati, Antonella ^a   Vaccari, Simona ^b   Ravanetti, Lara ^a   Maffei, Domenico L ^a   Polonelli, Luciano ^a  

^a UNIVERSITY OF PARMA   (Italy)

^b Parco Area Delle Scienze   (Italy)

Author keywords

Anti idiotypic antibiotics; Anti idiotypic therapy; Antimicrobial therapy; Killer antibodies; Killer mimotopes; Yeast killer toxin

Indexed keywords

ANTIFUNGAL AGENT; CELL RECEPTOR; EPITOPE; FUNGAL PROTEIN; MYCOTOXIN; NEUTRALIZING ANTIBODY; RECOMBINANT ANTIBODY;

AFFINITY CHROMATOGRAPHY; AMINO ACID SEQUENCE; ASPERGILLUS FUMIGATUS; BIOTECHNOLOGY; CANDIDA ALBICANS; CANDIDA DUBLINIENSIS; CANDIDA GLABRATA; CANDIDA GUILLIERMONDII; CANDIDA KRUSEI; CANDIDA LUSITANIAE; CANDIDA PARAPSILOSIS; CARBOXY TERMINAL SEQUENCE; CELL WALL; CONTROLLED STUDY; DERIVATIZATION; DRUG ACTIVITY; DRUG POTENCY; DRUG SCREENING; EUKARYOTE; FUNGAL CELL; FUNGAL STRAIN; GENE DELETION; MOLECULAR MECHANICS; NONHUMAN; PARACOCCIDIOIDES BRASILIENSIS; PNEUMOCYSTIS CARINII; PROKARYOTE; SHORT SURVEY; SPECTRAL SENSITIVITY; TECHNIQUE; YEAST;

AMINO ACID SEQUENCE; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, FUNGAL; ANTIBODIES, MONOCLONAL; CANDIDA ALBICANS; CANDIDIASIS; HUMANS; IMMUNIZATION, PASSIVE; MOLECULAR MIMICRY; MOLECULAR SEQUENCE DATA; MYCOTOXINS; PICHIA; VACCINATION;

EUKARYOTA; PROKARYOTA;

EID: 4644227941     PISSN: 15671356     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.femsyr.2004.06.010     Document Type: Short Survey

References (52)

1. D.M. Livermore Bacterial resistance: origins, epidemiology, and impact Clin. Infect. Dis. 36 2003 S11 S23
2. J. Loeffler, and D.A. Stevens Antifungal drug resistance Clin. Infect. Dis. 36 2003 S31 S41
3. R.C. Moellering Jr. Past, present and future of antimicrobial agents Am. J. Med. 99 Suppl 6A 1995 S11 S18
4. G.C. Schito Is antimicrobial resistance also subject to globalization? Clin. Microbiol. Infect. 8 Suppl 3 2002 1 8 discussion 33-35
5. R. Canton, T.M. Coque, and F. Baquero Multi-resistant Gram-negative bacilli: from epidemics to endemics Curr. Opin. Infect. Dis. 16 2003 315 325
6. M.L. Cohen Epidemiology of drug resistance: implications for a post-antimicrobial era Science 257 1992 1050 1055
7. F.D. Lowy Antimicrobial resistance: the example of Staphylococcus aureus J. Clin. Invest. 111 2003 1265 1273
8. I.M. Gould Antibiotic policies and control of resistance Curr. Opin. Infect. Dis. 15 2002 395 400
9. V. Idemyor Emerging opportunistic fungal infections: where are we heading? J. Natl. Med. Assoc. 95 2003 1211 1215
10. T.J. Walsh, and A.H. Groll Emerging fungal pathogens: evolving challenges to immunocompromised patients for the twenty-first century Transpl. Infect. Dis. 1 1999 247 261
11. W.T. Starmer, P.F. Ganter, V. Aberdeen, M.A. Lachance, and H.J. Phaff The ecological role of killer yeasts in natural communities of yeasts Can. J. Microbiol. 33 1987 783 796
12. W. Magliani, S. Conti, M. Gerloni, D. Bertolotti, and L. Polonelli Yeast killer systems Clin. Microbiol. Rev. 10 1997 369 400
13. D. Marquina, A. Santos, and J.M. Peinado Biology of killer yeasts Int. Microbiol. 5 2002 65 71
14. C. Guyard, N. Séguy, J.C. Cailliez, H. Drobecq, L. Polonelli, E. Dei-Cas, A. Mercenier, and F.D. Menozzi Characterization of a Williopsis saturnus var. mrakii high molecular weight secreted killer toxin with broad-spectrum antimicrobial activity J. Antimicrob. Chemother. 49 2002 961 971
15. L. Polonelli, and G. Morace Re-evaluation of the yeast killer phenomenon J. Clin. Microbiol. 24 1986 866 869
16. N. Séguy, E.M. Aliouat, E. Dei-Cas, L. Polonelli, D. Camus, and J.C. Cailliez Susceptibility of Pneumocystis carinii to a Pichia anomala killer toxin J. Eukaryot. Microbiol. 41 1994 109S
17. N. Séguy, J.C. Cailliez, L. Polonelli, E. Dei-Cas, and D. Camus Inhibitory effect of a Pichia anomala killer toxin on Pneumocystis carinii infectivity to the SCID mouse Parasitol. Res. 82 1996 114 116
18. L. Polonelli, R. Lorenzini, F. De Bernardis, and G. Morace Potential therapeutic effect of yeast killer toxin Mycopathologia 96 1986 103 107
19. M. Pettoello-Mantovani, A. Nocerino, L. Polonelli, G. Morace, S. Conti, L. Di Martino, G. De Ritis, M. Iafusco, and S. Guandalini Hansenula anomala killer toxin induces secretion and severe acute injury in the rat intestine Gastroenterology 109 1995 1900 1906
20. L. Polonelli, and G. Morace Yeast killer toxin-like anti-idiotypic antibodies J. Clin. Microbiol. 26 1988 602 604
21. L. Polonelli, and G. Morace Production and characterization of yeast killer toxin monoclonal antibodies J. Clin. Microbiol. 25 1987 460 462
22. L. Polonelli, F. Fanti, S. Conti, L. Campani, M. Gerloni, M. Castagnola, G. Morace, and C. Chezzi Detection by immunofluorescent anti-idiotypic antibodies of yeast killer toxin cell wall receptors of Candida albicans J. Immunol. Methods 132 1990 205 209
23. L. Polonelli, S. Conti, M. Gerloni, W. Magliani, M. Castagnola, G. Morace, and C. Chezzi 'Antibiobodies': antibiotic-like anti-idiotypic antibodies J. Med. Vet. Mycol. 29 1991 235 242
24. L. Polonelli, R. Lorenzini, F. De Bernardis, M. Gerloni, S. Conti, G. Morace, W. Magliani, and C. Chezzi Idiotypic vaccination: immunoprotection mediated by anti-idiotypic antibodies with antibiotic activity Scand. J. Immunol. 37 1993 105 110
25. L. Polonelli, F. De Bernardis, S. Conti, M. Boccanera, M. Gerloni, G. Morace, W. Magliani, C. Chezzi, and A. Cassone Idiotypic intravaginal vaccination to protect against candidal vaginitis by secretory, yeast killer toxin-like anti-idiotypic antibodies J. Immunol. 152 1994 3175 3182
26. L. Polonelli, N. Séguy, S. Conti, M. Gerloni, D. Bertolotti, C. Cantelli, W. Magliani, and J.C. Cailliez Monoclonal yeast killer toxin-like candidacidal anti-idiotypic antibodies Clin. Diagn. Lab. Immunol. 4 1997 142 146
27. W. Magliani, S. Conti, F. DeBernardis, M. Gerloni, D. Bertolotti, P. Mozzoni, A. Cassone, and L. Polonelli Therapeutic potential of antiidiotypic single chain antibodies with yeast killer toxin activity Nat. Biotechnol. 15 1997 155 158
28. C. Guyard, E. Dehecq, J.P. Tissier, L. Polonelli, E. Dei-Cas, J.C. Cailliez, and F.D. Menozzi Involvement of [beta]-glucans in the wide-spectrum antimicrobial activity of Williopsis saturnus var. mrakii MUCL 41968 killer toxin Mol. Med. 8 2002 686 694
29. C. Guyard, P. Evrard, A.M. Corbisier-Colson, H. Louvart, E. Dei-Cas, F.D. Menozzi, L. Polonelli, and J. Cailliez Immuno-crossreactivity of an anti-Pichia anomala killer toxin monoclonal antibody with a Williopsis saturnus var. mrakii killer toxin Med. Mycol. 39 2001 395 400
30. C. Beninati, M.R. Oggioni, M. Boccanera, M.R. Spinosa, T. Maggi, S. Conti, W. Magliani, F. De Bernardis, G. Teti, A. Cassone, G. Pozzi, and L. Polonelli Therapy of mucosal candidiasis by expression of an anti-idiotype in human commensal bacteria Nat. Biotechnol. 18 2000 1060 1064
31. M.R. Oggioni, C. Beninati, M. Boccanera, D. Medaglini, M.R. Spinosa, T. Maggi, S. Conti, W. Magliani, F. De Bernardis, G. Teti, A. Cassone, G. Pozzi, and L. Polonelli Recombinant Streptococcus gordonii for mucosal delivery of a scFv microbicidal antibody Int. Rev. Immunol. 20 2001 275 287
32. L. Polonelli, F. De Bernadis, S. Conti, M. Boccanera, W. Magliani, M. Gerloni, C. Cantelli, and A. Cassone Human natural yeast killer toxin-like candidacidal antibodies J. Immunol. 156 1996 1880 1885
33. C. Bromuro, A. Torosantucci, P. Chiani, S. Conti, L. Polonelli, and A. Cassone Interplay between protective and inhibitory antibodies dictates the outcome of experimentally disseminated candidiasis in recipients of a Candida albicans vaccine Infect. Immun. 70 2002 5462 5470
34. L. Polonelli, W. Magliani, S. Conti, L. Bracci, L. Lozzi, P. Neri, D. Adriani, F. De Bernardis, and A. Cassone Therapeutic activity of an engineered synthetic killer antiidiotypic antibody fragment against experimental mucosal and systemic candidiasis Infect. Immun. 71 2003 6205 6212
35. E. Cenci, A. Mencacci, A. Spreca, C. Montagnoli, A. Bacci, K. Perruccio, A. Velardi, W. Magliani, S. Conti, L. Polonelli, and L. Romani Protection of killer antiidiotypic antibodies against early invasive aspergillosis in a murine model of allogeneic T-cell-depleted bone marrow transplantation Infect. Immun. 70 2002 2375 2382
36. N. Séguy, J.C. Cailliez, P. Delcourt, S. Conti, D. Camus, E. Dei-Cas, and L. Polonelli Inhibitory effect of human natural yeast killer toxin-like candidacidal antibodies on Pneumocystis carinii Mol. Med. 3 1997 544 552
37. N. Séguy, L. Polonelli, E. Dei-Cas, and J.C. Cailliez Monoclonal killer toxin-like antiidiotypic antibodies to control rat-pneumocystosis J. Eukaryot. Microbiol. 44 1997 37S
38. Cenci, E., Bistoni, F., Mencacci, A., Perito, S., Magliani, W., Conti, S., Polonelli, L. and Vecchiarelli, A. (2004) A synthetic peptide as a novel anticryptococcal agent. Cell. Microbiol., in press
39. S. Conti, F. Fanti, W. Magliani, M. Gerloni, D. Bertolotti, A. Salati, A. Cassone, and L. Polonelli Mycobactericidal activity of human natural, monoclonal, and recombinant yeast killer toxin-like antibodies J. Infect. Dis. 177 1998 807 811
40. S. Conti, W. Magliani, S. Arseni, E. Dieci, R. Frazzi, A. Salati, P.E. Varaldo, and L. Polonelli In vitro activity of monoclonal and recombinant yeast killer toxin-like antibodies against antibiotic-resistant gram-positive cocci Mol. Med. 6 2000 613 619
41. S. Conti, W. Magliani, S. Arseni, R. Frazzi, A. Salati, L. Ravanetti, and L. Polonelli Inhibition by yeast killer toxin-like antibodies of oral streptococci adhesion to tooth surfaces in an ex vivo model Mol. Med. 8 2002 313 317
42. D. Savoia, C. Avanzino, S. Conti, W. Magliani, R. Frazzi, and L. Polonelli In vitro leishmanicidal activity of a monoclonal antibody mimicking a yeast killer toxin J. Eukaryot. Microbiol. 49 2002 319 323
43. R.C. Matthews, J.P. Burnie, D. Howat, T. Rowland, and F. Walton Autoantibody to heat-shock protein 90 can mediate protection against systemic candidosis Immunology 74 1991 20 24
44. R. Matthews, S. Hodgetts, and J. Burnie Preliminary assessment of a human recombinant antibody fragment to hsp90 in murine invasive candidiasis J. Infect. Dis. 171 1995 1668 1671
45. R.C. Matthews, G. Rigg, S. Hodgetts, T. Carter, C. Chapman, C. Gregory, C. Illidge, and J. Burnie Preclinical assessment of the efficacy of mycograb, a human recombinant antibody against fungal HSP90 Antimicrob. Agents Chemother. 47 2003 2208 2216
46. M.D. Moragues, M.J. Omaetxebarria, N. Elguezabal, M.J. Sevilla, S. Conti, L. Polonelli, and J. Ponton A monoclonal antibody directed against a Candida albicans cell wall mannoprotein exerts three anti-C. albicans activities Infect. Immun. 71 2003 5273 5279
47. R.C. Matthews, and J.P. Burnie Recombinant antibodies: a natural partner in combinatorial antifungal therapy Vaccine 22 2004 865 871
48. W. Magliani, S. Conti, S. Arseni, R. Frazzi, A. Salati, and L. Polonelli Killer anti-idiotypes in the control of fungal infections Curr. Opin. Invest. Drugs 2 2001 477 479
49. W. Magliani, S. Conti, A. Cassone, F. DeBernardis, and L. Polonelli New immunotherapeutic strategies to control vaginal candidiasis Trends Mol. Med. 8 2002 121 126
50. W. Magliani, S. Conti, R. Frazzi, G. Pozzi, M. Oggioni, and L. Polonelli Engineered commensal bacteria as delivery systems of anti-infective mucosal protectants Biotechnol. Genet. Eng. Rev. 19 2002 139 156
51. W. Magliani, S. Conti, A. Salati, S. Arseni, R. Frazzi, L. Ravanetti, and L. Polonelli New strategies for treatment of Candida vaginal infections Rev. Iberoam. Micol. 19 2002 144 148
52. W. Magliani, S. Conti, A. Salati, S. Arseni, L. Ravanetti, R. Frazzi, and L. Polonelli Biotechnological approaches to the production of idiotypic vaccines and antiidiotypic antibiotics Curr. Pharm. Biotechnol. 4 2003 91 97